A5086634668- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- ATP Synthase and ATPases Research
- Advanced Breast Cancer Therapies
- Mitochondrial Function and Pathology
- Genetics and Neurodevelopmental Disorders
- Chronic Myeloid Leukemia Treatments
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Quinazolinone synthesis and applications
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- Fungal Plant Pathogen Control
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- BRCA gene mutations in cancer
- Colorectal Cancer Treatments and Studies
- Microtubule and mitosis dynamics
- Genetic factors in colorectal cancer
- Breast Cancer Treatment Studies
- PI3K/AKT/mTOR signaling in cancer
Seoul National University Hospital
2012-2023
Seoul National University
2013-2023
Zero to Three
2016
AstraZeneca (United Kingdom)
2012-2013
New Generation University College
2013
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been found to have therapeutic potential for treating cancers associated with impaired DNA repair capabilities, particularly those deficiencies in the homologous recombination (HRR) pathway. Histone deacetylases (HDACs) are important enabling functional HRR of by regulating expression HRR-related genes and promoting accurate assembly HRR-directed sub-nuclear foci. Thus, HDAC inhibitors recently emerged as agent cancer inhibiting...
Abstract A PARP inhibitor is a rationally designed targeted therapy for cancers with impaired DNA repair abilities. RAD51C paralog of RAD51 that has an important role in the damage response. We found cell lines sensitive to novel oral inhibitor, olaparib, had low levels expression using microarray analysis, and we therefore hypothesized may hamper process, resulting increased sensitivity olaparib. Compared cells normal levels, RAD51C-deficient cancer were more higher proportion underwent...
Abstract Ataxia telangiectasia and Rad3-related (ATR) can be considered an attractive target for cancer treatment due to its deleterious effect on cells harboring a homologous recombination defect. The aim of this study was investigate the potential use ATR inhibitor, AZD6738, treat gastric cancer. In SNU-601 with dysfunctional ATM, AZD6738 led accumulation DNA damage RAD51 foci formation, S phase arrest, caspase 3–dependent apoptosis. contrast, SNU-484 functional ATM were not sensitive...
Abstract Background Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2− MBC); however, resistance common and poorly understood. A comprehensive genomic transcriptomic analysis of pretreatment post-treatment tumors from receiving palbociclib ET was performed to delineate molecular mechanisms drug resistance. Methods Tissue...
Due to its regulation of CDK1/2 phosphorylation, WEE1 plays essentially roles in the regulations G2/M checkpoint and DNA damage response (DDR). inhibition can increase genomic instability by inducing replication stress inactivation, which result increased cellular sensitivity damaging agents. We considered an induced might be used augment effects drugs targeting repair protein. Typically, PARP inhibitors are effective germline BRCA 1/2 mutated breast ovarian cancer, but their applicabilities...
Abstract Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration, tumorigenesis. Increased activity has been reported types human cancer, including gastric cancer. Therefore, this factor identified as promising therapeutic target for cancer treatments, targeting predicted to have potent effects. We evaluated antitumor effect c-Src/Abl inhibitor, saracatinib (AZD0530), alone or...
Ataxia telangiectasia and Rad3‐related (ATR) proteins are sensors of DNA damage, which induces homologous recombination (HR)‐dependent repair. ATR is a master regulator damage repair (DDR), signaling to control replication, apoptosis. Therefore, the pathway might be an attractive target for developing new drugs. This study was designed investigate antitumor effects inhibitor, AZD6738 its underlying mechanism in human breast cancer cells. Growth inhibitory against cell lines were studied...
Abstract Gastric cancer (GC) is commonly treated by chemotherapy using 5-fluorouracil (5-FU) derivatives and platinum combination, but predictive biomarker remains lacking. We develop patient-derived xenografts (PDXs) from 31 GC patients treat with a combination of 5-FU oxaliplatin, to determine biomarkers associated responsiveness. When the PDXs are defined as either responders or non-responders according tumor volume change after treatment, responsiveness significantly consistent...
Characteristics of tumor microenvironment have been suggested as predictive markers anti-EGFR or anti-HER2 treatment response. However, the effect EGFR/HER2 signal blockade on immune is unclear.EGFR/HER2 pathway signaling and PD-L1 expression in gastric cancer cell lines were screened by western blot analysis. HER2 expressions 251 resected tumors determined immunohistochemistry, changes EFGR, HER2, paired specimens between pre- post-chemotherapy evaluated. HER2-amplified was evaluated...
Abstract Breast cancer (BC) in patients with germline mutations of BRCA1/BRCA2 are associated benefit from drugs targeting DNA damage response (DDR), but they account for only 5–7% overall breast cancer. To define the characteristics these tumors and also to identify without BRCA mutation homologous recombination deficiency (HRD) is clinically relevant. characteristic features HRD analyze correlations between BC subtypes, we analyzed 981 TCGA database using signature analyzer. The was...
Purpose KX-01 is a novel dual inhibitor of Src and tubulin. Unlike previous inhibitors that failed to show clinical benefit during treatment breast cancer, can potentially overcome the therapeutic limitations current through inhibition both The present study further evaluates activity mechanism in vitro vivo. Materials Methods antitumor effect triple negative cancer (TNBC) cell lines was determined by MTT assay. Wound healing immunofluorescence assays were performed evaluate action...
Abstract The androgen receptor (AR) is expressed in 60%–70% of breast cancers regardless estrogen status, and has been proposed as a therapeutic target that retain AR. In this study, the authors aimed to investigate new treatment strategy using novel AR inhibitor AZD3514 cancer. alone had minimal antiproliferative effect on most cancer cell lines irrespective expression level, but it downregulated expressions DNA damage response (DDR) molecules, including ATM chk2, which resulted...
Pim kinases are highly conserved serine/threonine kinases, and different expression patterns of each isoform (Pim-1, Pim-2, Pim-3) have been observed in various types human cancers, including gastric cancer. AZD1208 is a potent selective inhibitor that affects all three isoforms Pim. We investigated the effects as single agent combination with an Akt cancer cells.The antitumor activity with/without was evaluated large panel cell lines through growth inhibition assays. The underlying...
Immune cells in the tumour microenvironment play an essential role tumorigenesis. This study aimed to evaluate immunoregulatory protein expression of breast cancer and reveal their prognostic role.
Purpose Overexpression of cyclooxygenase 2 (COX-2) is thought to promote survival transformed cells. Transforming growth factor β (TGF-β) exerts anti-proliferative effects on a broad range epithelial In the current study, we investigated whether TGF-β can regulate COX-2 expression in A549 human lung adenocarcinoma cells, which are TGF-β-responsive and overexpress COX-2. Materials Methods Western blotting, Northern mRNA stability assays were performed demonstrate that protein suppressed by...
Endocrine therapy is a standard treatment for hormone receptor-positive breast cancer, which accounts 60%-75% of all cancer. Hormone receptor positivity prognostic and predictive biomarker in Approximately 50%-80% cancer also positive androgen (AR), but the value AR expression controversial. Here, we investigated its patients with surgically resected Korea.We retrospectively reviewed medical records who had to collect data other clinicopathological data. The optimal cut-off was determined...
1013 Background: The development of CDK4/6 inhibitors represents a significant advance in the treatment metastatic breast cancer (MBC). To better understand impact and drug resistance at molecular level, we performed multi-omics profiling matched pre-treatment, on-treatment, post-progression tumor biopsies from patients treated with palbociclib combined endocrine blockades (AIs fulvestrant). purpose study was to identify biomarkers as well assess changes during treatment, those appearing...